高盛研究报告，料市场将对药明康德(02359.HK) 的次季盈喜有积极反应，当中经调整非国际财务报告准则净利润按年升47.9%至36亿元人民币(下同)，远超市场预期的15至20%。而销售额按年升20.4%至111亿元，亦高于该行预期的102亿元及市场预期的104亿元，延续首季强劲势头。次季调整后净利率达32.6%，相较首季的27.7%及去年全年的27%显著提升。该行认为表现超预期主要因TIDEs...
Source Link高盛研究报告，料市场将对药明康德(02359.HK) 的次季盈喜有积极反应，当中经调整非国际财务报告准则净利润按年升47.9%至36亿元人民币(下同)，远超市场预期的15至20%。而销售额按年升20.4%至111亿元，亦高于该行预期的102亿元及市场预期的104亿元，延续首季强劲势头。次季调整后净利率达32.6%，相较首季的27.7%及去年全年的27%显著提升。该行认为表现超预期主要因TIDEs...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.